1. Home
  2. PBYI vs ACU Comparison

PBYI vs ACU Comparison

Compare PBYI & ACU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • ACU
  • Stock Information
  • Founded
  • PBYI 2010
  • ACU 1867
  • Country
  • PBYI United States
  • ACU United States
  • Employees
  • PBYI N/A
  • ACU N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • ACU Industrial Machinery/Components
  • Sector
  • PBYI Health Care
  • ACU Consumer Discretionary
  • Exchange
  • PBYI Nasdaq
  • ACU Nasdaq
  • Market Cap
  • PBYI 164.3M
  • ACU 145.9M
  • IPO Year
  • PBYI N/A
  • ACU N/A
  • Fundamental
  • Price
  • PBYI $3.54
  • ACU $43.63
  • Analyst Decision
  • PBYI Strong Buy
  • ACU
  • Analyst Count
  • PBYI 1
  • ACU 0
  • Target Price
  • PBYI $7.00
  • ACU N/A
  • AVG Volume (30 Days)
  • PBYI 306.9K
  • ACU 36.9K
  • Earning Date
  • PBYI 07-31-2025
  • ACU 07-18-2025
  • Dividend Yield
  • PBYI N/A
  • ACU 1.38%
  • EPS Growth
  • PBYI 143.51
  • ACU N/A
  • EPS
  • PBYI 0.77
  • ACU 2.48
  • Revenue
  • PBYI $232,709,000.00
  • ACU $195,491,991.00
  • Revenue This Year
  • PBYI N/A
  • ACU $4.87
  • Revenue Next Year
  • PBYI N/A
  • ACU $3.65
  • P/E Ratio
  • PBYI $4.64
  • ACU $17.61
  • Revenue Growth
  • PBYI 2.68
  • ACU 2.56
  • 52 Week Low
  • PBYI $2.23
  • ACU $32.85
  • 52 Week High
  • PBYI $4.13
  • ACU $50.00
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 58.61
  • ACU 69.81
  • Support Level
  • PBYI $3.26
  • ACU $38.87
  • Resistance Level
  • PBYI $3.65
  • ACU $44.25
  • Average True Range (ATR)
  • PBYI 0.14
  • ACU 1.39
  • MACD
  • PBYI 0.01
  • ACU 0.58
  • Stochastic Oscillator
  • PBYI 84.78
  • ACU 91.29

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

Share on Social Networks: